SCHEMBL13595124

SCHEMBL13595124

CO[C@H]1C[C@@H]2C(=O)OC(=O)[C@@H]2C1

nearest known ligand 0.30

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ GMNN O75496 1/20 0.30
▸ PPM1B O75688 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ PPP1CC P36873 1/20 0.30
▸ TFPI2 P48307 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ PPP5C P53041 1/20 0.30
▸ PPP1CA P62136 1/20 0.30
▸ PMP22 Q01453 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ TDP1 Q9NUW8 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP2D6 P10635 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ THPO P40225 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13595126 0.87 KDM4E (0.30) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL13595118 0.87 KDM4E (0.30) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL13595127 0.87 KDM4E (0.30) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL11758161 0.81 CYP2D6 (0.32) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL24843176 0.76 KDM4E (0.39) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL14424191 0.76 KDM4E (0.39) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL615001 0.76 KDM4E (0.39) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL15498544 0.76 KDM4E (0.39) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL16360071 0.76 KDM4E (0.39) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL14669163 0.76 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325889-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR CAMPBELL DAVID ALAN 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325889-A1 HEPATITIS C SERINE PROTEASE INHIBITORS AND USES THEREFOR PREP, HPN, PRSS1 HSD11B1 769/4885KDM4E 3578/4885GMNN 3721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback